What Is Cartalax?
Cartalax peptide — also referred to as AED or T-31 peptide — is a synthetic tripeptide that some investigators categorize among a group of compounds known as Khavinson peptides. These are short amino acid chains that researchers have described as potential “”bioregulators”” — a designation that reflects the hypothesis that they may modulate fundamental physiological mechanisms related to DNA and gene expression. It is worth noting upfront that this classification remains an area of active scientific discussion, and the mechanisms by which Cartalax may achieve its proposed effects are still being debated in research circles.
Structurally, Cartalax is composed of three amino acids — Alanine, Glutamate, and Aspartate (AED) — a sequence that researchers have noted appears in the alpha-1 chain of type XI collagen, a structural protein thought to be involved in maintaining tissue integrity under specific conditions. According to some reports, the peptide may have been originally isolated from kidney tissue extracts containing polypeptides, though the precise details of its discovery remain an area of ongoing clarification in the research literature.
What has drawn researchers to this cellular aging peptide is its proposed potential to influence biological pathways related to cellular aging — a broad and complex area of science in which Cartalax remains a relatively early-stage subject of laboratory investigation.
Cartalax Peptide and Cell Renewal: What Early Research Suggests
One of the primary areas of Cartalax peptide research involves its potential interactions with markers of cell proliferation and programmed cell death — two processes that sit at the heart of cellular renewal in laboratory models. It is important to approach the findings in this area with appropriate caution, as the research base remains limited and results have not been consistent across all cell types studied.
Research by Khavinson et al. proposed that Cartalax peptide may reduce the expression of p53 — a tumor suppressor protein also associated with pro-apoptotic signaling — in aging renal epithelial cell cultures. A decrease in p53 might suggest a relative reduction in apoptosis in these specific models, potentially creating conditions that could favor cell renewal. However, the same researchers did not observe a corresponding increase in Ki-67 — a widely used nuclear marker of cell proliferative activity — in these particular renal epithelial cell cultures.
Interestingly, a separate study by Lin’kova et al. reported a potentially significant Ki-67 increase in fibroblast cultures exposed to Cartalax peptide — a finding that appears to differ from the renal epithelial results. Fibroblasts are specialized cells found in connective tissue, responsible for producing collagen and other extracellular matrix components. The Ki-67 increase in these cells may imply that Cartalax peptide has some ability to support cell renewal in certain cell types — though researchers have been careful to note that this finding requires further investigation and replication before firm conclusions can be drawn.
Lin’kova et al. also observed that Cartalax peptide may upregulate CD98hc — a multifunctional cell membrane protein involved in amino acid transport and integrin signaling — in fibroblasts, potentially supporting nutrient uptake and cell adherence in laboratory models. The same researchers observed a reduction in caspase-3 expression — a central marker of active cell death — in both early and advanced-passage fibroblast cultures, leading them to comment that the peptide appeared to reduce apoptosis levels in both young and aged cultures in laboratory settings. Additionally, Cartalax peptide appeared to reduce MMP-9 expression in later-passage fibroblast cultures — a protease commonly linked to extracellular matrix remodeling — possibly suggesting a reduction in excessive ECM breakdown in these specific models.
Separate experiments by Chalisova et al. in kidney culture systems appeared to confirm some of these observations — finding that Cartalax peptide may both raise Ki-67 expression and lower p53 levels. While these findings are consistent with the hypothesis that Cartalax may modulate cell cycle progression and apoptotic signaling in laboratory models, researchers have been careful to note that the precise mechanisms remain unclear and further investigation is needed.
Cartalax Peptide and Cellular Aging Markers: An Emerging Picture
Beyond its potential interactions with cell renewal markers, Cartalax peptide has also been explored for its possible influence on several molecular markers associated with cellular aging in laboratory models. This remains one of the more speculative areas of the research — with researchers acknowledging that the findings raise interesting questions without yet providing definitive answers.
Research by Khavinson et al. suggested that Cartalax peptide may reduce levels of p16 and p21 in laboratory models — two proteins that function as cyclin-dependent kinase inhibitors, typically limiting cell cycle progression and commonly associated with cellular senescence. If these reductions are confirmed in further studies, they could potentially reflect an influence on checkpoints involved in cellular aging — though researchers have been cautious about overstating this possibility given the early stage of the evidence.
At the same time, the same research group observed that Cartalax peptide may upregulate SIRT-6 — an enzyme believed to participate in chromatin remodeling and metabolic regulation. Decreased SIRT-6 levels are sometimes correlated with cellular aging in laboratory models, so a potential increase in SIRT-6 following Cartalax exposure has led researchers to hypothesize that it may reflect mechanisms that counteract age-related molecular changes — though this remains speculative at this stage.
Perhaps the most structurally intriguing proposed mechanism involves Cartalax peptide’s hypothesized ability to form energetically favorable complexes with specific DNA motifs — particularly the sequence d(ATATATATAT)2 — within the DNA minor groove. Researchers have proposed that such sequence-specific binding may influence local chromatin conformation and gene transcription related to cellular aging. The precise structural details of this interaction, however, remain under investigation and have not yet been fully characterized in laboratory settings.
Cartalax Peptide and Telomere-Related Signaling
One of the more notable — and appropriately tentative — areas of Cartalax peptide research involves its potential interactions with molecular pathways related to telomere stability and maintenance in laboratory models. Telomeres are repetitive DNA sequences at chromosome ends that tend to shorten with each cell division, and their progressive shortening is frequently associated with cellular aging in research settings.
Research by Lin’kova et al. suggested that Cartalax peptide may alter the expression of TNKS2 — the gene encoding tankyrase 2 — in replicative cellular aging models. Tankyrase 2 is believed to be involved in telomere stability through regulation of telomeric repeat-binding factors, as well as in metabolic control, mitotic processes, and Wnt signaling pathways. By potentially modulating TNKS2, Cartalax peptide might theoretically influence telomere maintenance or metabolic pathways in aging cell cultures — though researchers have been careful to frame these observations as preliminary and in need of substantial further investigation before any meaningful conclusions can be drawn.
Cartalax Peptide and Cellular Stress Resistance
The final area of Cartalax peptide laboratory research explored in this overview involves its potential influence on gene expression patterns associated with cellular stress responses in aging cell culture models. Research by Ashapkin et al. noted that Cartalax peptide may increase IGF-1 gene expression levels in various aging cell culture models — with the researchers reporting an approximately 3.5 to 5.6-fold enhancement upon peptide addition across different culture systems. IGF-1 is frequently viewed as a mediator of growth-associated processes, and its potential elevation in senescent cells might reflect an adaptive cellular response during stressful conditions in laboratory settings — though researchers noted that the precise significance of this observation remains to be clarified.
The same research group also observed that Cartalax peptide appeared to reduce the expression of TERT — the key enzymatic subunit involved in telomere length maintenance — in laboratory models. Researchers proposed that if older cells elevate TERT as a stress response, a decrease in TERT under Cartalax peptide exposure might suggest a possible transition toward a more stable gene expression pattern — though this interpretation remains speculative and requires further study.
Finally, multiple investigators have noted that Cartalax peptide may elevate NFκB transcript levels in laboratory models — a transcription factor commonly considered a pivotal regulator of inflammation and stress responses. The precise consequences of this potential NFκB upregulation remain uncertain, with researchers proposing that it may represent only one aspect of a broader cellular network encompassing senescence, inflammatory pathways, and metabolic adaptation in aging laboratory models. As with many of the findings discussed throughout this article, the NFκB observation underscores the complex and multi-layered nature of Cartalax peptide’s proposed interactions — and the considerable research still needed to understand them fully.
References
- Khavinson VKh, et al. Peptides regulate the expression of signaling molecules in kidney cell cultures during in vitro aging. Bull Exp Biol Med. 2014;157(2):261–4.
- Lin’kova NS, et al. Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro. Bull Exp Biol Med. 2016;161(1):175–8.
- Chalisova NI, et al. Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals. Bull Exp Biol Med. 2015;159(1):124–7.
- Khavinson VKh, et al. Tripeptides slow down the aging process in renal cell culture. Adv Gerontol. 2014;27(4):651–6.
- Linkova N, et al. Peptide Regulation of Chondrogenic Stem Cell Differentiation. Int J Mol Sci. 2023;24(9):8415.
- Ashapkin V, et al. Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Mol Biol Rep. 2020;47(6):4323–4329.
Disclaimer: The information provided is intended solely for educational and scientific discussion. The compounds described are strictly intended for laboratory research and in-vitro studies only. They are not approved for human or animal consumption, medical use, or diagnostic purposes. Handling is prohibited unless performed by licensed researchers and qualified professionals in controlled laboratory environments.
